Tariquidar

DRUG3 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Adenaocortical CarcinomaCancerCervix NeoplasmsColdrhood CancerLung NeoplasmsOvarian NeoplasmsRefractory CancerRenal Neoplasms

Phase 1

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

CompletedNCT00011414

National Cancer Institute (NCI)Adenaocortical Carcinoma, Coldrhood Cancer, Refractory Cancer +2

Start: 2001-02-15End: 2016-01-13Updated: 2019-07-16

Phase 2

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

CompletedNCT00069160

National Cancer Institute (NCI)Cervix Neoplasms, Lung Neoplasms, Ovarian Neoplasms +1

Start: 2003-09-30End: 2009-12-31Updated: 2012-10-12

PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy

CompletedNCT00082368

National Cancer Institute (NCI)Cancer

Start: 2004-05-16End: 2014-04-14Updated: 2017-08-17